BAM15 vs Semaglutide
A side-by-side research comparison of BAM15 and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BAM15 | Semaglutide |
|---|---|---|
| Full name | BAM15 (Mitochondrial Uncoupler) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | FDA Approved |
| Mechanism | Selectively transports protons across the inner mitochondrial membrane, dissipating the proton gradient as heat rather than ATP. Cells burn more substrate (fat and glucose) to maintain energy, increasing metabolic rate without stimulating the CNS. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | 402.28 Da | 4,114 Da |
| Half-life | Short (hours in animal models) | 7 days (168 hours) |
| Bioavailability | Oral (animal studies) | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | Not established for humans | 0.25 mg → titrate up to 2.4 mg |
| Frequency | Research protocols only | Once weekly |
| Route | Oral (research) | Subcutaneous injection |
BAM15 reported benefits
- Increases metabolic rate/energy expenditure
- Fat loss without appetite suppression
- Improved insulin sensitivity (animal models)
- Reduced liver fat
- Wider safety margin than DNP (preclinical)
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.